![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SH3TC1 |
Gene summary for SH3TC1 |
![]() |
Gene information | Species | Human | Gene symbol | SH3TC1 | Gene ID | 54436 |
Gene name | SH3 domain and tetratricopeptide repeats 1 | |
Gene Alias | SH3TC1 | |
Cytomap | 4p16.1 | |
Gene Type | protein-coding | GO ID | GO:0008150 | UniProtAcc | B3KWX8 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
54436 | SH3TC1 | HCC1_Meng | Human | Liver | HCC | 9.58e-28 | 1.05e-01 | 0.0246 |
54436 | SH3TC1 | HCC2_Meng | Human | Liver | HCC | 1.70e-02 | 4.55e-02 | 0.0107 |
54436 | SH3TC1 | HCC2 | Human | Liver | HCC | 3.06e-02 | 2.52e+00 | 0.5341 |
54436 | SH3TC1 | S014 | Human | Liver | HCC | 9.24e-04 | 2.46e-01 | 0.2254 |
54436 | SH3TC1 | S015 | Human | Liver | HCC | 8.85e-13 | 5.33e-01 | 0.2375 |
54436 | SH3TC1 | S016 | Human | Liver | HCC | 3.30e-11 | 3.83e-01 | 0.2243 |
54436 | SH3TC1 | S027 | Human | Liver | HCC | 2.09e-02 | 3.83e-01 | 0.2446 |
54436 | SH3TC1 | S028 | Human | Liver | HCC | 1.59e-11 | 4.64e-01 | 0.2503 |
54436 | SH3TC1 | S029 | Human | Liver | HCC | 5.16e-15 | 6.89e-01 | 0.2581 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | CRC | ![]() |
Stomach | GC | ![]() |
Stomach | CAG with IM | ![]() |
Stomach | CSG | ![]() |
Stomach | CAG | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SH3TC1 | SNV | Missense_Mutation | novel | c.346N>A | p.Asp116Asn | p.D116N | Q8TE82 | protein_coding | deleterious(0.02) | possibly_damaging(0.596) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
SH3TC1 | SNV | Missense_Mutation | novel | c.825N>T | p.Leu275Phe | p.L275F | Q8TE82 | protein_coding | deleterious(0) | probably_damaging(0.981) | TCGA-AN-A0FZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
SH3TC1 | SNV | Missense_Mutation | c.1142N>C | p.Glu381Ala | p.E381A | Q8TE82 | protein_coding | tolerated(0.05) | probably_damaging(0.953) | TCGA-AO-A0J3-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cyclophosphamide | SD | |
SH3TC1 | deletion | Frame_Shift_Del | novel | c.1145delN | p.Lys383SerfsTer18 | p.K383Sfs*18 | Q8TE82 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
SH3TC1 | deletion | Frame_Shift_Del | novel | c.3586delC | p.His1196ThrfsTer41 | p.H1196Tfs*41 | Q8TE82 | protein_coding | TCGA-E9-A2JS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cyclophosphamide | PD | ||
SH3TC1 | deletion | Frame_Shift_Del | novel | c.1434delN | p.Asp479ThrfsTer21 | p.D479Tfs*21 | Q8TE82 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
SH3TC1 | deletion | Frame_Shift_Del | novel | c.2562delN | p.Val855TrpfsTer10 | p.V855Wfs*10 | Q8TE82 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
SH3TC1 | SNV | Missense_Mutation | novel | c.2648N>G | p.Ala883Gly | p.A883G | Q8TE82 | protein_coding | deleterious(0) | benign(0.398) | TCGA-DS-A1OB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |
SH3TC1 | SNV | Missense_Mutation | c.3642C>G | p.Phe1214Leu | p.F1214L | Q8TE82 | protein_coding | deleterious(0.01) | possibly_damaging(0.712) | TCGA-EA-A43B-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
SH3TC1 | SNV | Missense_Mutation | novel | c.541C>T | p.Pro181Ser | p.P181S | Q8TE82 | protein_coding | tolerated(0.46) | benign(0.131) | TCGA-EA-A5ZF-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |